Treating young children co-infected with tuberculosis and HIV
Turkova & Bamford
The Lancet HIV, 2019, 6(1): PE4-E6
Catalysing the development and introduction of paediatric drug formulations: a new global collaborative framework for action
Penazzato, Watkins, Morin, Lewis, Pascual, Vicari, Lee, Hargreaves, Doherty & Siberry
The Lancet HIV, 2018, 5(5): 259-e264
Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens
Cruz & Stark
Pediatrics, 2018, 141(2)
Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children
Schaaf, Garcia-Prats, McKenna & Seddon
Expert Rev Clin Pharmacol, 2018, 11(3):233-244
Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries
Penazzato, Lewis, Watkins, Prabhu, Pascual, Auton, Kreft, Morin, Vicari, Lee, Jamieson & Siberry
J Int AIDS Soc, 2018, 21(S1), e25049
Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations
Clarke, Penazzato, Capparelli, Cressey, Siberry, Sugandhi & Mirochnick, WHO Paediatric Antiretroviral Working Group
Expert Rev Clin Pharmacol, 2018, 11(1):83-93
Meeting the goal of concurrent adolescent and adult licensure of HIV prevention and treatment strategies
Hume, Lewis & Nelson
J. Med. Ethics, 2017, 0: 1-4
Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations
Choi, Jeong, Koh & Lee
Ann Lab Med, 2017, 37(2): 97-107
Prioritizing the most needed formulations to accelerate paediatric antiretroviral therapy scale-up
Penazzato, Palladino & Sugandhi, on behalf of the PADO 3 Meeting participants
Curr Opin HIV AIDS, 2017, 12:369-376
Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations
Penazzato, Gnanashanmugam, Rojo, Lallemant, Lewis, Rocchi, Saint Raymond, Ford, Hazra, Giaquinto, Belew, Gibb, & Abrams, for the PAWG
Clin Infect Dis, 2017, 64(11):1597-1603
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
Bouazza, Cressey, Foissac, Bienczak, Denti, McIlleron, Burger, Penazzato, Lallemant, Capparelli, Treluyer & Urien
J Antimicrob Chemother, 2017, 72(2):490-495
Advances in Drug Discovery and Development for Pediatric Tuberculosis
Hoagland, Zhao & Lee
Mini Rev Med Chem, 2016, 16(6): 481-497
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
Nachman, Ahmed, Amanullah, Becerra, Botgros, Brigden, Browning, Gardiner, Hafner, Hesseling, How, Jean-Philippe, Lessem, Makhene, Mbelle, Marais, McIlleron, McNeeley, Mendel, Murray, Navarro, Anyalechi, Porcalla, Powell, Powell, Rigaud, Rouzier, Samson, Schaaf, Shah, Starke, Swaminathan, Wobudeya & Worrell
Lancet Infect Dis, 2015, 15(6):711-720
The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children
Graham, Grzemska & Gie
Int J Tuberc Lung Dis, 2015, 19(1): S3-S8
The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective
Scott, Gardiner & de Lucia
Int J Tuberc Lung Dis, 2015, 19(1): S17-S22
Pediatric tuberculosis drug market: an insider perspective on challenges and solutions
Usherenko, Basu Roy, Mazlish, Liu, Benkoscki, Coutts, Epstein, Qian, Rafiq, & Scott
Int J Tuberc Lung Dis, 2015, 19(1): S23-S31
From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations
Malhotra, Ursu, Ghoneim, Jodrey, Paredes, Brown, Soucy & Barr-DiChiara
Int J Tuberc Lung Dis, 2015, 19(1): S32-S38
A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children
Furin, Mafukidze, Brigden, du Cros, Golin, Harausz, Seddon, Ustero, & Garcia-Prats
Int J Tuberc Lung Dis, 2015, 19(1): S55-S60
Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations
Taneja, Garcia-Prats, Furin & Maheshwari
Int J Tuberc Lung Dis, 2015, 19(1): S61-S68
Accelerating clinical drug development for children with tuberculosis
Murray, McKenna, Pelfrene & Botgros
Int J Tuberc Lung Dis, 2015, 19(1): S69-S74
Optimizing drugs to reach treatment targets for children and adolescents living with HIV
Penazzato, Lee, Capparelli, Essajee, Ford, Ojoo, Pascual, Sugandhi & Lallemant
J Int AIDS Soc, 2015,18(Suppl 6):20270
Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization
White
Antimicrob Agents Chemother, 2013, 57(12): 5792-5807